A review of aluminium phosphide poisoning and a flowchart to treat it

Behrooz Hashemi-Domeneh1,2, Nasim Zamani1,2, Hossein Hassanian-Moghaddam1,2, Mitra Rahimi1,2, Shahin Shadnia1,2, Peyman Erfantalab1,2, and Ali Ostadi1,2

Toxicological Research Center, Department of Clinical Toxicology, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences1, Excellence Center of Clinical Toxicology, Iranian Ministry of Health2, Tehran, Iran

[Received in February 2016; CrossChecked in February 2016; Accepted in September 2016]

The use of pesticides such as aluminium phosphide (AIP) has increased in the recent years and improved the quantity and quality of agricultural products in a number of developing countries. The downside is that AIP causes severe chronic and acute health effects that have reached major proportions in countries such as India, Iran, Bangladesh, and Jordan. Nearly 300,000 people die due to pesticide poisoning in the world every year. Poisoning with AIP accounts for many of these deaths. Unfortunately, at the same time, there is no standard treatment for it. The aim of this article is to give a brief review of AIP poisoning and propose a treatment flowchart based on the knowledge gained so far. For this purpose we reviewed all articles on the management of AIP poisoning published from 2000 till now. Using a modified Delphi design, we have designed a handy flowchart that could be used as a guide for AIP poisoning management of patients in emergency centres.

KEY WORDS: emergencies; literature review; pesticides; poisoning management

Pesticide use has increased the quantity and quality of agricultural products in a number of developing countries. Although its wise use may improve the quality of life and livelihood of their residents, improper use may cause severe chronic and acute poisoning. In fact, nearly 300,000 people in the world die every year due to pesticide poisoning (1).

Metal phosphides make a large proportion of the pesticides/fumigants that are currently being used. The use of aluminium, magnesium, and calcium phosphides has become popular in developing countries mainly because they are potent, cheap, and have no undesirable effects on agricultural products. Yet, the risk of mortality associated with phosphide poisoning in humans ranges between 30 % and 100 % (2).

Aluminium phosphide (AIP) is used for crop protection in storage and transport such as silos, ships, and trains (3). It is quite common in Iran (especially northern Iran) in the form of tablets (hence the common term “rice tablets”) due to low cost, high potency, and ready availability, but so is the risk of poisoning and death. Northern Iranian provinces report a rather high AIP poisoning rate (3), for which reason Iran has been trying to control AIP production and purchase, but the tablets are still being smuggled into the country and available to the lay people at low prices.

Current figures say that AIP is one of the most common causes of poisoning deaths in India, Sri Lanka, Iran, Oman, and Morocco (4-8) but not in European and North American countries (9, 10). Reports of mortality due to AIP poisoning vary across the world. Between 1997 and 2003, UK reported only 93 cases of AIP poisoning, all of them accidental, and only one resulted in a death (4). In Germany, between 1983 and 2003, only 188 cases of AIP poisoning were reported, 65 % of which accidental and mainly inhalational. They had mainly caused transient irritation of the gastrointestinal and respiratory system and none resulted in a death. The remaining, intentional poisonings caused two deaths (11).

By contrast, AIP poisoning caused 146 deaths in Iran between 2000 and 2007 (8,12). According to Hosseinian et al. (13), more than 90 % of these poisonings are suicidal. In Tehran it seems to be the most common suicide agent (14), especially in people below 30 years of age. The mortality rate ranges between 18.6 % and 24 % and is higher in the rural areas (15).

In contact with water, an AIP tablet releases deadly phosphine gas (PH₃), which has drawn interest for its use as a chemical weapon (4). While the danger of AIP poisoning is obvious, this can not be said for its treatment. AIP has no specific antidote, and only through shared experience can we increase the odds of survival by improving the management of AIP poisoning. (8). This article is one such attempt to gather recent knowledge in one place and suggest a management flowchart that perhaps best suits the circumstances in Iran and countries with similar issues and healthcare.
Literature search and data pooling

We searched PubMed, Google Scholar, and Scopus for all articles on AlP poisoning management published from 2000 to date. The key words we used were “aluminium phosphide”, “poisoning”, “toxicity”, “treatment”, and “management”. We reviewed the abstracts of recovered articles, looking specifically for those suggesting treatment for AlP poisoning. Duplicate articles, articles that did not meet the above criteria, and articles that did not add new data were excluded. The final pool of articles after exclusion consisted of seven reviews, 44 original articles, 33 case reports, three letters, one textbook, and five web references.

All selected articles were reviewed by the first author for original human data about the toxic effects of AlP and its management and the pooled data were discussed by all authors at six sessions. The final AlP poisoning management flowchart was designed by the corresponding author and reviewed and endorsed by six authors.

POOLED FINDINGS

Chemistry

Aluminium phosphide (AlP) comes as a dark grey or yellow crystal and AlP tablets are available under a variety of trade names, such as Phosfume, Synfum, Celphos, Phostoxin, Quickphos, Phostek, Chemfume, Degesch, Talunex, Alphosm, and Delicia (16). A three-gram tablet can release almost one gram of phosphine gas in contact with water. In Iran, the AlP tablet is marketed under the trade name of Phostoxin and contains aluminium phosphide, urea, and ammonium carbamate. Phosphine gas is flammable (16-20). To prevent spontaneous combustion the tablet should also contain ammonium carbamate at the 56:44 ratio of AlP and ammonium carbamate, respectively (18).

In contact with water, AlP tablet produces phosphine, ammonia, and CO₂. Contact with acids may even increase the release of PH₃ (21). Phosphine gas (PH₃) has a molecular weight of 34 Da. It is colourless, flammable, has the odour of spoiled fish (density: 1.52 g L⁻¹), and is detectable at concentrations of 2 mg L⁻¹ (2 ppm) or more. The spoiled fish odour comes from the impurities such as diphosphine (P₂H₄), methane, arsine, and extracted hydrogen and phosphines (3, 22).

Toxicokinetics

Absorption: After ingestion, phosphine will be released due to contact between AlP and water/acid in the gastrointestinal (GI) tract. Some phosphide may be absorbed by the GI tract without hydrolysis and convert into phosphine. Phosphine gas can rapidly be absorbed by the lungs and GI tract. Absorption through skin and eyes is not common but may happen (23).

Distribution: After ingestion, phosphine concentration increases in the blood and liver. This small molecule can easily be distributed in all tissues (24, 25).

Metabolism and elimination: Metal phosphides change to phosphine due to hydrolysis. The most important urine metabolite of phosphine is hypophosphite, but urine can also contain phosphate and phosphite. Phosphine itself is eliminated by exhalation (26). Aluminium phosphide may be eliminated in the urine unchanged.

Toxicodynamics

Most of the toxic effects of metal phosphides are owed to PH₃, which is a protoplasmic poison that interferes with the function of the cellular enzymes and proteins. According to some authors (27, 28), the mechanism of its toxicity is electron transfer blockage and non-competitive blockage of cytochrome C oxidase, which inhibits oxidative phosphorylation and, in turn, cellular respiration and activation of peroxide radicals. Phosphine can inhibit catalase and deplete glutathione, which may result in cellular wall and canal dysfunction as well (29, 30).

According to Proudfoot (31), studies have shown that phosphine impairs cellular respiration. It inhibits the entrance of amino acids into the cycle of myocardial protein synthesis and also inhibits cytochrome C oxidase in cardiac cells. According to Anand et al. (32), these changes in the mitochondria and myocardial proteins impair cellular permeability to sodium, potassium, magnesium, calcium, and other ions and change cardiac cell wall potential. Phosphine-induced pathophysiological changes are more prominent in the myocardium, pulmonary cells, and tiny peripheral vessels (26).

Both AlP and phosphine inhibit cholinesterase, but this inhibition is unlikely to be clinically relevant (33). Another toxic action of phosphine is that it changes the capacity of haeme. In vitro studies show that humans and rats can absorb unhydrolysed aluminium phosphide salt, which keeps reacting with free haemoglobin and haemoglobin in normal red blood cells (RBCs) to produce haemichrome, a derivative of methaemoglobin (31, 34).

Levels of carbon monoxide, which can be established by CO-oximetry, can help diagnosis and prognosis of AlP poisoning. Namely, phosphine may affect oxyhaemoglobin that interacts with CO and cause dyshaemoglobinemia, which can yield high CO findings (35).

Considering that phosphine produces free oxygen radicals in body tissues, it has been shown that organs with a higher need for oxygen (heart, lung, kidney, and liver) are more sensitive to the damage induced by phosphine gas, which is compatible with the post-mortem histopathological changes in these organs. In addition, Heinz bodies, which are indicative of the destruction of haemoglobin in vitro, increase to 1.25 µg mL⁻¹ in poisoned patients (36).
Toxic levels

The lethal dose of AlP in a normal 70-kg adult has been reported to be 500 mg (37). In the work place, air phosphine level of 50 mg L\(^{-1}\) (50 ppm) may be dangerous for health, and 400-600 mg L\(^{-1}\) (400-600 ppm) may cause death in 30 minutes (38).

CLINICAL MANIFESTATIONS

Acute poisoning due to ingestion

The first signs and symptoms of poisoning manifest themselves in 10-15 min, progress very fast (32), and affect the cardiovascular and respiratory systems. If the tablet is ingested, GI irritation can also be detected. Early signs include nausea and vomiting, epigastric and retrosternal pain, dyspnœa, anxiety, irritability, and garlic or spoiled fish odour from the patients' breath can be detected at the early stages of toxicity. This odour can also be detected after inhalation (16).

Early gastrointestinal signs and symptoms include haematemesis, vomiting, and epigastric pain. Dysphagia is a common but delayed complication. Endoscopy usually shows destructive lesions of the oesophagus and stomach, stomach lesions, duodenal erosions, and osseophageal obstruction or fistula (21).

Poisoning manifestations of the central nervous system generally include irritability, anxiety, dizziness, ataxia, numbness, paraesthesia, and tremor. However, these signs and symptoms are not prominent, unless important complications such as hypoxia or hypotension occur. Delayed and severe neurological signs include delirium, seizure, and coma (39). Persistent shock can cause drowsiness, delirium, and coma.

The most common hepatotoxicity findings in patients who ingested AlP tablets are elevated aspartate transaminase and alanine transaminase (40-43). Jaundice, if manifested, may be a sign of liver impairment (40). In deceased patients the most common histopathological findings are cytoplasmic vacuolation of the hepatocytes and sinusoidal congestion (44).

The most common respiratory signs and symptoms are tachypnoea, dyspnœa, crepitation, and rhonchi. Respiratory distress syndrome and pulmonary oedema are common in adult patients and accompany the accumulation of bloody or full-protein liquids in the pleural space (32).

Cardiac signs and symptoms include increased size of the ventricles, left ventricular and septal hypokinesia, akinesia, decreased cardiac output, severe hypotension, increased systemic venous pressure, normal capillary wedge pressure, and inappropriate systemic vasoconstriction (21). Electrocardiographic (ECG) changes depend on the time elapsed since AlP ingestion. Sinus tachycardia is prominent within the first three to six hours, followed by conductive delays and arrhythmias from hours six to twelve (45). The most common arrhythmias are supra-ventricular tachycardia (46 %), ventricular tachycardia (40 %), ventricular fibrillation (23 %), and atrial flutter and fibrillation (20 %) (46). Post-mortem findings show cardiac failure, severe and persistent hypotension, heart congestion, subendocardial infarction, pericarditis, cardiac fibre detachment due to oedema, fibre destruction, non-specific vacuolation of the myocytes, local necrosis, neutrophil infiltration, and eosinophilia (40, 41, 47-50).

Electrolyte abnormalities include high or low sodium, potassium, and magnesium. Hypocalcaemia may also be detected. Hypokalaemia may precede or follow vomiting. Hyperkalaemia, hypernatremia, and hyponatremia are associated with poorer prognosis (49). Hyper- or hypoglycaemia may also occur (40, 48, 50). Changes in the serum level of magnesium, calcium, phosphate, citrate, and cortisol may increase serum glucose levels, which is associated with poorer prognosis (25).

Other uncommon manifestations include hepatitis, pancreatitis, ascites, myocardial infarction, acute pericarditis, pleural effusion, acute tubular necrosis (ATN), adrenocortical congestion with bleeding or necrosis, diffuse intravascular coagulation (DIC), rhabdomyolysis, and methaemoglobinaemia (3, 31, 42). Oesophageal stricture and oesophagotracheal fistula are two delayed complications (51-55). Most deaths occur within the first 12-24 h due to cardiac arrest (47). Deaths occurring after 24 h are often related to hepatic failure (32).

Acute poisoning due to inhalation

After inhaling small amounts of phosphine gas, patients generally experience respiratory tract irritation and dyspnœa (3). Other manifestations include dizziness, chest tightness, headache, nausea and vomiting, diarrhoea, ataxia, numbness, paraesthesia, tremor, muscular weakness, and diplopia (6, 38). Inhalation of high amounts of the gas can lead to cardiac failure, acute respiratory distress syndrome (ARDS), dysrhythmia, seizure, coma, and delayed manifestations such as liver and kidney toxicity (6, 38).

Chronic poisoning

Patients with chronic phosphine exposure, usually those who work in silos, have manifestations such as cough, dyspnœa, chest pain, drowsiness, loss of appetite, and epigastric pain (56). Chronic exposure to low levels of phosphine may induce toothache and mandibular swelling and necrosis (phossy jaw). Chronic dermal exposure to 0.4 mg L\(^{-1}\) (0.4 ppm) of phosphine gas may cause dermal congestion and sensitivity (56, 57).

Laboratory findings

Diagnostic laboratory tests that can predict the outcome are mandatory for the management of AlP poisoning. Generally these include ECG, cardiac monitoring, chest
X-ray, blood sugar, arterial or venous blood gas analysis (ABG or VBG), serum electrolytes, complete blood count (CBC), and liver and kidney function tests. Hypo- and hypermagnesemia are associated with cardiotoxicity and vast myocyte destruction (3). Poisoned patient may have high, low, or even normal levels of magnesium (40, 49, 58). CBC can show low white and red blood cell counts.

Intravascular haemolysis, methaemoglobinemia, or microangiopathic haemolysis are less common complications of AIP poisoning (34, 58-60). Serum sodium and potassium may either be high or low. Hypokalaemia is generally detected after tablet ingestion and is probably caused by vomiting or catecholamine release (31). Hypoglycaemia can be due to gluconeogenesis, glycogenolysis, or adrenal insufficiency. Hypoglycaemia is common and can be severe and persistent (57). It is also associated with a poorer outcome (25, 60, 61). ABG analysis can detect metabolic acidosis or mixed metabolic acidosis and respiratory alkalosis (31).

Chest x-ray generally shows pulmonary oedema, pleural effusion, and sub-pericardial bleedings.

ECG changes include sinus tachycardia, ST changes, inverted T, myocardial infarction, AV block (especially the right bundle branch block), and complete heart block (31, 62) in addition to the previously mentioned complications. If the patient survives the first 24 hours, ECG changes will normalize in 10-25 days. Life-threatening changes can be detected by the ECG in as many as 50 % of the patients. (41).

**Biosample testing for PH₃**

Phosphine is rapidly oxidised to phosphate and hypophosphite and is not tested for in clinical assessments (19). Identifying its presence in tissue is not necessary for the diagnosis of AIP poisoning.

However, qualitative analysis of PH₃ is important for forensic purposes. Forensic evaluation includes the analysis of expiratory air (50 % of the AIP-poisoned patients have positive expiratory tests) (3), stomach content (vomits and/or gastric lavage), which can be collected in clean glass samplers, urine (only for PH₃ metabolites due to rapid oxidation of the gas), and liver. Heated in acidic environment, liver tissue releases PH₃ in the tissue matrix, which makes it a valuable sample for post mortem identification of phosphine. Blood, however, is not suitable due to the oxidative metabolism of phosphines (36).

**Routine methods of AIP detection and quantification**

Phosphine is routinely detected in biosamples by chemical qualitative colour tests such as silver nitrate (0.1 N or 16.987 g L⁻¹), mercury chloride in ethanol, acidic potassium permanganate (0.1 N or 79.017 g L⁻¹), or 0.5 % mercury diethylthiocarbamate. The sample is heated in acidic environment to release PH₃, which interacts with the chemical and generates a specific colour.

Detection of PH₃ with silver nitrate paper is perhaps the most common and valuable in clinical and forensic tests and can be used on biosamples such as expiratory air and stomach content. Silver nitrate reacts with PH₃ and changes the colour of the paper to dark grey or black (63). The method is sensitive enough to detect PH₃ at concentrations as low as 0.05 mg L⁻¹ (0.05 ppm).

Less common tests use ammonium, arsine, and ammonium molybdate as detectors. The first two are used on expiratory air samples (26) but are seldom used for clinical testing over validity issues. The ammonium molybdate test is used on stomach content.

Potentiometry, in turn, is a semi-quantitative test used to determine the concentration of PH₃. PH₃ reacts with mercury chloride [PH₃ + 3HgCl₂ → P (HgCl₄)₂ + 3HCl] to produce a series of changes in the oxidation-reduction potential and consequently in the electrical conduction of electrochemical cells. The concentration of PH₃ can also be calculated from HCl released from sodium hydroxide (64). Currently the most sensitive and specific quantification method is chromatography with a nitrogen-phosphorus detector, as it can measure even the lowest levels of PH₃ in the air (65).

**Differential diagnosis**

The signs and symptoms of mild poisoning are similar to the signs and symptoms of upper respiratory infections. In severe cases of poisoning, contact with PH₃ can be misdiagnosed with cardio-pulmonary oedema, viral, and bacterial pneumonia, or ARDS due to other causes (32). Signs and symptoms of poisoning with zinc phosphide can be similar to AIP poisoning, but are usually slower to manifest themselves, and zinc phosphide poisoning has a lower mortality rate (66, 67).

**Treatment of acute poisoning**

The proposed AIP poisoning treatment flowchart (Figure 1) is mostly intended for Iran and can be used as a unified method throughout the country.

After the presentation of a patient with suspected history of AIP poisoning, the first step is to diagnose if the patient has really been exposed to AIP using the above-mentioned diagnostic tests. Whoever of the medical staff is checking the patient should wear a full-face mask and rubber gloves. Bear in mind that masks with tiny pores cannot prevent PH₃ exposure (65). If the patient's clothes are contaminated, they should be taken off. Contaminated skin and eyes should be thoroughly washed (3). The vomit can contain PH₃, and can be dangerous to others, so it should be cleaned and disposed of. Whoever does the cleaning should be warned about the dangers. In inhalational exposures the patient should immediately be removed from the contaminated environment, his/her clothes changed, and his/her skin washed, taking recommended precautions.
Take history of AIP tablet ingestion or inhalation
(establish place and label of the purchased tablets/ time of ingestion/ signs and symptoms on admission/ vital signs and VBG)

Gastrointestinal signs/symptoms/acidosis/decreased blood pressure or CO level >10 (62) or positive silver nitrate paper test (27)

Yes

- GI decontamination (in the 1st post-ingestion hour) with NaHCO₃ gavage (two 44 mmol vials [100 mL] per L) and KMnO₄ (1/10000/1 g per 10 L)
- protect the airways (consider RSI)
- establish central IV access
- perform biochemistry, ECG, chest x-ray, ABG, or echocardiography (27)
- If hypotension develops (SBP<90 mmHg):
  - insert CV line to check CVP
  - give N/S or ringer (2×10 mL kg⁻¹)
  - give norepinephrine (0.1 μg kg⁻¹ min⁻¹) or phentolamine (4-6 μg min⁻¹) to keep SBP >90 mmHg and urine output at 0.5-1 mL kg⁻¹ h⁻¹
  - anti-arrhythmics / DC cardioversion available

IF CO level is >18:
- start HIE protocol (1U kg⁻¹ insulin stat, followed by 0.5U kg⁻¹ h⁻¹ infusion; can be increased to 10 U kg⁻¹ h⁻¹) + 0.5-1 g kg⁻¹ dextrose stat, followed by 0.5-1 g kg⁻¹ h⁻¹
- maintain BS between 100 and 150 mg dL⁻¹
- maintain K between 2.8 and 3.2 meq L⁻¹ (62)
- consider pacemaker and IABP (72, 75)
- CVP/PAWP-guided fluid therapy (27)

Consider HD or CRRT in case of severe persistent acidosis/overload or renal failure (29)

No

Admission / follow with serial VBGs

Acidosis / other symptoms of poisoning

Consider administration of MgSO₄ (as antioxidant) at 1 g stat, followed by 1 g qh for 3 h and then 1 g every 6 h (7)

In case of toxic myocarditis or persistent hypovolemic shock or arrhythmia consider:
- IABP (72)
- extracorporeal membrane oxygenation (ECMO) (76)

If acute lung injury or ARDS develops:
- treat ARDS
- provide ventilatory support (27)
- consider methaemoglobinemia in persistent cyanosis and administer 2 mg kg⁻¹ methylene blue over 5 min (35)

Consider bicarbonate therapy if:
- serum bicarbonate is <15 or pH is <7.2 (60)
- bicarbonate deficit = (20 - serum bicarbonate level of the patient) × 0.4 × patient's weight

Abbreviations: GI, gastrointestinal; NaHCO₃, sodium bicarbonate; KMnO₄, potassium permanganate; ECG, electrocardiogram; ABG, arterial blood gases; IABP, intra-aortic balloon pump; PAWP, pulmonary artery wedge pressure; SBP, systolic blood pressure; CVP, central venous pressure; HIE, hyperinsulinemia-hypoglycemia; HD, haemodialysis; CRRT, continuous renal replacement therapy; MgSO₄, magnesium sulphate; ARDS, acute respiratory distress syndrome; NAC, N-acetyl cysteine
As there is no specific antidote for AlP poisoning, the cornerstone of therapy is supportive care. Timing significantly affects the prognosis. If AlP poisoning is suspected based on the history and physical examination, treatment must not be delayed until test results are confirmed (24). Symptomatic patients should be monitored in the intensive care unit (ICU) for at least 72 hours. They should be receiving 100-percent oxygen and treated for fluid and electrolyte abnormalities. Serum calcium and magnesium and liver/kidney function tests are mandatory (68).

GI decontamination

Gastrointestinal decontamination is efficient within the first hour after rice tablet ingestion. As stomach acid increases the conversion of AlP to PH₃, treatment with 3-5% sodium bicarbonate can help, although its efficacy has not been proved (26, 69). Gastric lavage using a 1:10,000 solution of potassium permanganate oxidizes PH₃ to a nontoxic phosphate. If it is administered in the first hour after ingestion, it can substantially decrease the amount of toxic PH₃ (69, 70).

Administration of activated charcoal (1 g kg⁻¹ in children and 50-100 g in adults) lowers phosphide absorption and alleviates latent signs/symptoms of poisoning. Although it is useful in a patient who has recently ingested a huge amount of AlP, its efficacy is limited and is therefore not recommended for routine treatment (69).

Some recommend the use of coconut oil to accompany routine treatment (63, 70), as it contains saturated fatty acids and seems to reduce the release of PH₃ in gastric acid. Furthermore, coconut oil seems to coat the stomach mucosa and prevent PH₃ absorption. This effect was reported after co-administration of 50 mL of coconut oil and 50 mL of sodium bicarbonate (70), but there is little other research evidence to make it part of routine treatment. Vegetable oils and liquid paraffin have also been reported to prevent PH₃ release from AlP in vitro, but there is only one case report to confirm it (70). Another promising treatment, according to Saidi and Shojaiy (71), could be sweet almond oil, as it lowered AlP-induced death in rats, but its action has not been reported in human-beings. Hassanian-Moghaddam and Shahbazi (72) proposed the use of gastric ventilation to evacuate PH₃ within minutes of rice tablet ingestion. More studies are needed to prove the efficacy of this method.

Cardiovascular support

Due to the cardiovascular effects of the toxin, ECG and cardiac monitoring are recommended in all patients. Primary resuscitation by administration of fluids and inotropes and checking central vein pressure (CVP) and pulmonary artery wedge pressure (PAWP) are also recommended (26, 73-75). Norepinephrine, phenylephrine, dopamine, or dobutamine can be used to treat hypotension and persistent shock. However, vasopressors with greater activity at beta receptors (such as dopamine and dobutamine) can cause dysrhythmias and should be used with caution (26).

Cardiac arrhythmias are generally treated by anti-arrhythmic medications, direct-current defibrillation, or temporary pacemaker. Digoxin is used to stabilise the left ventricle. Earlier case reports showed that primary administration of 0.5 mg of digoxin followed by 0.5 mg every six hours for the first day and 0.25 mg daily afterwards improved the patient's cardiovascular symptoms (73, 74). However, only a few studies have evaluated the efficacy of digoxin in the treatment of AlP poisoning, and it may be initiated in patients whose cardiac insufficiency has been confirmed by echocardiogram.

Some physicians recommend inducing hyperinsulinaemia-euglycaemia (HIE) as well as hyperventilation, as both trigger energy production from carbohydrates, reverse calcium, and improve myocyte contractions (62). Some report the use of intra-aortic balloon pump (IABP) for mechanical support of the heart in patients with toxic myocarditis, persistent shock or persistent cardiac complications of the poisoning (72, 75). Some persistent cases may require the implantation of a pacemaker (12). Extrapulmonary membrane oxygenation is another recently suggested treatment with promising results (75, 76).

Respiratory support

One of the complications of AlP poisoning is the development of ARDS, which is treated as usual (26, 31). If the patient develops persistent cyanosis, methaemoglobinemia should be suspected and 1-2 mg kg⁻¹ of methylene blue should be intravenously administered over five minutes (21).

Other treatments

Sodium bicarbonate is used for the treatment of acidosis. If the patient has volume overload, haemodialysis (HD) can be performed, although it cannot expel PH₃ from the blood (28). Infusing the patient with 1-4 L of 5-10% dextrose in water (DW) is recommended to maintain serum glucose in the normal range. Hypoglycaemia, hypokalaemia, and metabolic acidosis are treated as usual (26, 31).

Ten millilitres of 10% calcium gluconate is generally recommended to stabilise cell membranes. Administration of calcium gluconate or chloride is also recommended in case of hypocalcaemia-induced tetany (67, 77). Magnesium sulphate (MgSO₄) is another cell membrane stabiliser with anti-oxidant properties to mitigate the effects of free radicals released by phosphine. In general, it has been shown that this treatment can decrease AlP-related mortality by 25% (62). Different doses have been proposed for MgSO₄ administration including: a) 3 g in 3 h followed by 6 g in 24 h for 3-5 days (3); b) 1 g as initial dose, followed by 1 g every hour for 2 h and 1-1.5 g every six hours for 5-7 days (7); and c) 1 g as initial dose, followed by 1 g for 3 h and then 1 g every six hours for five to seven days (78).
However, due to the risk of hypermagnesemia (62), it seems that routine use of MgSO$_4$ is not practical (26, 31). We therefore recommend magnesium administration with any of the above-mentioned protocols in patients with low or even normal serum magnesium levels. Daily serum magnesium monitoring can prevent hypermagnesemia during treatment.

Considering that N-acetylcyesteine (NAC) can reverse cellular glutathione and magnesium storages and acts as an antioxidant, its effects in the supportive treatment of AlP have been investigated in rats and humans. In rats, NAC prolonged survival time, stabilised blood pressure and pulse rate, and prevented oxidative stress of the myocardium (79). In humans, NAC lowered mortality, hospitalisation time, and the frequency of intubation and mechanical ventilation (80). It increased blood pressure and kept it stable within the first 24 hours. Two methods have been proposed for NAC administration:

a) intravenous (IV) infusion of 150 mg kg$^{-1}$ in 200 mL of 5 % DW over one hour, followed by 50 mg kg$^{-1}$ in 500 mL of 5 % DW over four hours, and then 100 mg kg$^{-1}$ in 1000 mL of 5 % DW over 16 hours (37);

b) IV infusion of 140 mg kg$^{-1}$ followed by 70 mg kg$^{-1}$ every four hours for 17 doses.

However, the recommended IV injection dose for routine treatment is 50-100 mg kg$^{-1}$ three times a day (67).

Administration of vitamin E seems to prevent hepatic destruction due to lipid peroxidation by phosphine (81). This effect, however, still needs to be confirmed by future studies. Administration of vitamin C (1 g every six hours) with 1 % methylene blue was successful against methaemoglobinaemia and haemolysis caused by PH$_3$ (34). However, this treatment is generally not recommended because it may worsen patient's acidosis.

Other treatments such as melatonin, glutathione, and beta carotene have also been proposed and need further evaluation (72).

There is no report or evidence of steroid treatment efficacy in AlP poisoning, but we know that steroids act against inflammation, especially in the respiratory system (64).

Using hyperbaric oxygen prolonged survival time in rats but did not reduce mortality (82). This method has not been evaluated in humans.

Hydroxyethyl starch can stay in the vessels and prevent fluid and albumin shift to the tissues (83). However, there is no clinical information to support this effect in AlP poisoning.

Blood exchange is a questionable treatment in AlP poisoning (84, 85). Haemodialysis does not efficiently eliminate PH$_3$ from blood, but can be used in patients with acute kidney failure, severe metabolic acidosis, or fluid overload (26). Administration of vasopressors, fresh blood, and bronchodilators are recommended when indicated.

If pulmonary oedema develops, and the patient is not hypotensive, diuretics can also be used. Seizure should be treated with routine therapies, including benzodiazepines (67).

Both clinical and laboratory reports say that phosphine and aluminium inhibit acetylcholinesterase (AChE) and that pralidoxime may prove effective in restoring AChE activity. In rats, atropine and pralidoxime increased survival when administered five minutes after exposure to AlP. More studies are needed to prove the efficacy of oximes in the treatment of this poisoning (33). For the moment, these medications are not recommended for routine treatment.

Considering all of the above, the only recommended treatment of AlP poisoning is the general supportive one.

**Prognosis and long-term complications**

In ingestions of 500 mg or more the mortality rate is 30 to 100 %. Most of the deaths are due to cardiovascular collapse within the first 12-24 hours (47, 62). After the first 24 hours, deaths are mainly due to persistent shock, severe acidosis, and ARDS (85). Fulminant hepatic failure occurs within 72 hours and is another cause of death in these patients (3). Patients who have taken lower doses, expired tablets, or tablets exposed to air have a greater chance of survival. Vomiting and early supportive care can also increase the survival rate (12, 26).

Poorer prognosis is associated with higher phosphine levels, no vomiting after ingestion, hyperglycaemia, hyperkalaemia, hyponatraemia, hypernatraemia, hyperuricaemia, acidosis, leukocytosis, haemoconcentration, low prothrombin time, shock, methaemoglobinemia, abnormal ECG, need for inotropes, need for mechanical ventilation, high Simplified Acute Physiology Score (SAPS) and Acute Physiology and Chronic Health Evaluation II (APACHE II), and low Glasgow coma scale (4, 8, 25, 26, 60, 86–89). The higher the phosphine blood level, the higher is the risk of death.

If no signs/symptoms are evident six hours after ingestion or inhalation, the patient will remain symptom-free (76). With cardio-respiratory complications the prognosis is poor (67). Most of the deaths happen in the first 24 hours, and much depends on the severity of poisoning and the time between poisoning and treatment.

Some patients reported local GI complications in the first month after poisoning including dysphagia, oesophageal stricture, and oesophagotracheal fistula (90). It is recommended that all patients undergo GI evaluation using barium swallow and endoscopy before they are released from the hospital in order to detect these complications and treat them as soon as possible (3).

Cytogenetic and genetic evaluations have shown that PH$_3$ is not mutagenic (90).

**Prevention**

Access to AlP tablets should be limited and controlled, in particular their over and below-the-counter sale. Most of the victims are people with suicidal intent, and we believe...
that disseminating knowledge about this poison among lay people is not only useless but may also increase poisoning rate among people with suicidal intent. More effort should be made to disseminate and update knowledge among physicians, so that they can improve treatment and save more lives.

REFERENCES

Hashemi-Domeneh, et al. A review of aluminium phosphide poisoning and a flowchart to treat it
Arh Hig Rada Toksikol 2016;67:183-193


49. Chugh S, Kishore K, Aggarwal N, Attri S. Aluminium phosphide (ALP) is a widely used fumigant pesticide. J Assoc Physicians India 2000;48:855-6. PMID: 11273498


64. National Research Council (US) Committee on Acute Exposure Guideline Levels. Phosphine and eight metal phosphides. In: Acute exposure guideline levels for selected toxicant.
77. Zamani N, Mehrpour O. Protective role of 6-GPD deficiency in poisoning by aluminium phosphide; are there possible new treatments? Eur Rev Med Pharmacol Sci 2013;17:994-5. PMID: 23640450
Pregled otrovanja aluminijevim fosfidom i prijedlog dijagrama tijeka njegova liječenja


KLJUČNE RIJEČI: hitna služba; liječenje otrovanja; pesticidi; pregled literature